OncoMatch/Clinical Trials/NCT06417008
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Is NCT06417008 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including HS-20117 and Aumolertinib for non-squamous non-small cell lung cancer.
Treatment: HS-20117 · Aumolertinib — HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: MET inhibitor
Previous or current treatment with MET targeted therapy
Cannot have received: EGFR-targeted antibody
Previous or current treatment with EGFR targeted antibodies
Cannot have received: antibody-drug conjugate
Previous or current treatment with antibody-drug conjugates (ADC)
Cannot have received: traditional Chinese medicine indicated for tumors
Traditional Chinese medicine indicated for tumors
Cannot have received: major surgery or other local therapy
major surgery or other local therapy within washout period to the first dose of study drug
Cannot have received: other investigational non-anti-tumor drugs
Other investigational non-anti-tumor drugs within the washout period
Lab requirements
Blood counts
Inadequate bone marrow reserve [excluded]
Kidney function
Inadequate organ functions [excluded]
Liver function
Inadequate organ functions [excluded]
Cardiac function
Severe, uncontrolled or active cardiovascular disorders [excluded]
Inadequate bone marrow reserve or organ functions. Severe, uncontrolled or active cardiovascular disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06417008 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages